Novartis psoriasis drug approval could upend market

January 21, 2015 11:10 PM

3 0

Novartis psoriasis drug approval could upend market

Novartis scored an approval for its plaque psoriasis antibody, Cosentyx (secukinumab), on Wednesday, making it the first approved interleukin inhibitor. Cosentyx may prove to be a lucrative addition for the Swiss drugmaker. The drug is poised to grow market share, and could also unseat entrenched competition in the disease state, namely from the previous class of medicines, TNF inhibitors, like Amgen's Enbrel and Johnson & Johnson's Stelara.

Secukinumab demonstrated in head-to-head trials that it was superior to Stelara and Enbrel in clearing skin, according to media releases from Novartis. Amgen reported Enbrel sales of $1.12 billion for Q3 2014, while Stelara reported sales of $534 million for the same time period—a 47% jump from the ...

Also read: GM posts best 3Q results since exiting bankruptcy

Read more

To category page